

4.1 TABLE OF CONTENTS

MODULE 4 – NON-CLINICAL STUDY REPORTS

SECTION/ SUBSECTION	TITLE	VOLUME
4.1	Table of contents	1
4.2	Study reports	1
4.3	Literature References	1

4.2 STUDY REPORTS

Not applicable.

4.3 COPIES OF LITERATURE REFERENCES

(Used in module 2.4)

LIST OF LITERATURE REFERENCES

Akaishi T, Kurashima H, Odani-Kawabata N, Ishida N, Nakamura M, 2010. Effects of repeated administrations of tafluprost, latanoprost, and travoprost on optic nerve head blood flow in conscious normal rabbits. *J Ocul Pharmacol Ther*; 26(2):181-6.

Ammar DA, Noecker RJ, Kahook MY, 2010. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia preserved topical glaucoma medications on human ocular epithelial cells. *Adv Ther*; 27(11):837-45.

Ayaki M, Iwasawa A, 2010. Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneconjunctival cell lines. *Clin Ophthalmol*; 4:919-24.

Ayaki M, and Iwasawa A, 2011. Cell viability of four corneconjunctival cell lines exposed to five preservatives and a surfactant used for infection control in eye drops. *Biocontrol Sci*. 16: 117–121.

Baudouin C, Riancho L, Warnet JM, Brignole F, 2007. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. *Invest Ophthalmol Vis Sci*; 48(9):4123-8.

Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F, 2010. Preservatives in eye drops: the good, the bad and the ugly. *Prog Retin Eye Res*; 29(4):312–334.

Bolívar G, Teus M, Arranz-Marquez E, 2011. Effect of Acute Increases of the Intraocular Pressure on the Corneal Pachymetry in Eyes Treated with Travoprost: An Animal Study. *Curr Eye Res*; Sep 23. [Epub ahead of print].

Brignole-Baudouin F, Riancho L, Liang H, Baudouin C, 2011. Comparative In Vitro Toxicology Study of Travoprost Polyquad-preserved, Travoprost BAK-preserved, and

Latanoprost BAK-preserved Ophthalmic Solutions on Human Conjunctival Epithelial Cells. *Curr Eye Res*;36(11):979-88.

Cho HK, Park MH, Moon JI, 2011. Effects of antiglaucoma drugs on the ocular surface in rabbits: a fixed-combination drug versus two concomitant drugs. *Jpn J Ophthalmol*; Sep 9. [Epub ahead of print]

Eichhold TH, Kuhlenbeck DL, Baker TR, Stella ME, Amburgey JS, deLong MA, Hartke JR, Cruze CA, Pierce SA, Wehmeyer KR, 2000. Use of short high-performance liquid chromatography columns and tandem-mass spectrometry for the rapid analysis of a prostaglandin analog, fluprostenol, in rat plasma. *J Chromatogr B Biomed Sci Appl*; 741(2):213-20.

EMA, (2009): EMA Public Statement on Antimicrobial Preservatives in Ophthalmic Preparations for Human Use (Doc. Ref.: EMA/622721/2009).

Franks WA, Renard JP, Cunliffe IA, Rojanapongpun P. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0.005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. *Clin Ther*. 2006 Mar;28(3):332-9.

Gabelt BT, Hennes EA, Bendel MA, Constant CE, Okka M, Kaufman PL, 2009. Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. *J Ocul Pharmacol Ther*; 25(1):1-8.

Gagliuso DJ, Wang RF, Mittag TW, Podos SM, 2004. Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes. *Arch Ophthalmol*; 122(9):1342-7.

Gasset AR (1977): Benzalkonium chloride toxicity to the human cornea. *Am J Ophthalmol*; 84(2):169–171.

Gelatt KN, MacKay EO, 2004. Effect of different dose schedules of travoprost on intraocular pressure and pupil size in the glaucomatous Beagle. *Vet Ophthalmol*; 7(1):53-7.

Giannico AT, Lima L, Russ HH, Montiani-Ferreira F, 2013. Eyelash growth induced by topical prostaglandin analogues, bimatoprost, tafluprost, travoprost, and latanoprost in rabbits. *J Ocul Pharmacol Ther*; 29(9):817-20.

Goldberg I, Cunha-Vaz J, Jakobsen JE, et al. 2001. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. *J Glaucoma*, 10:414–22

Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F, 2005. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. *Invest Ophthalmol Vis Sci*; 46(7):2444-50.

Hariharan S, Minocha M, Mishra GP, Pal D, Krishna R, Mitra AK, 2009. Interaction of ocular hypotensive agents (PGF2 alpha analogs-bimatoprost, latanoprost, and travoprost) with MDR efflux pumps on the rabbit cornea. *J Ocul Pharmacol Ther*; 25(6):487-98.

Hellberg MR, Sallee VL, McLaughlin MA, Sharif NA, Desantis L, Dean TR, Zinke PW, 2001. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. *J Ocul Pharmacol Ther*; 17(5):421-32.

Hollo G. 2007. The side effects of the prostaglandin analogues. *Expert Opin Drug Saf*, 6:45–52.

Inan UU, Ermis SS, Orman A, Onrat E, Yucel A, Ozturk F, Asagidag A, Celik A. The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol. *J Ocul Pharmacol Ther.* 2004 Aug;20(4):293-310.

Kahook MY, Noecker R, 2008. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. *Adv Ther;* 25(8):743-51.

Khoh-Reiter S, Jessen BA, 2009. Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model. *BMC Ophthalmol;* 9:5.

Kurashima H, Watabe H, Sato N, Abe S, Ishida N, Yoshitomi T, 2010. Effects of prostaglandin F(2 α) analogues on endothelin-1-induced impairment of rabbit ocular blood flow: comparison among tafluprost, travoprost, and latanoprost. *Exp Eye Res;* 91(6):853-9.

Liang H, Brignole-Baudouin F, Pauly A, Riancho L, Baudouin C, 2011. Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study. *Adv Ther;* 28(4):311-25.

Liu G, Zeng T, Yu W, Yan N, Wang H, Cai SP, Pang IH, Liu X, 2011. Characterization of intraocular pressure responses of the Tibetan monkey (*Macaca thibetana*). *Mol Vis;* 17:1405-13.

Mackay EO, McLaughlin M, Plummer CE, Ben-Shlomo A, Gelatt KN, 2011. Dose response for travoprost(®) in the glaucomatous beagle. *Vet Ophthalmol;* 2012 Mar;15 Suppl 1:31-5.

McCue BA, Cason MM, Curtis MA, Faulkner RD, Dahlin DC, 2002. Determination of travoprost and travoprost free acid in human plasma by electrospray HPLC/MS/MS. *J Pharm Biomed Anal*; 28(2):199-208.

Nagai N, Murao T, Okamoto N, Ito Y, 2010. Comparison of corneal wound healing rates after instillation of commercially available latanoprost and travoprost in rat debrided corneal epithelium. *J Oleo Sci*; 59(3):135-41.

Netland PA, Landry T, Sullivan EK, et al. 2001. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. *Am J Ophthalmol*, 132:472–84.

Ohashi M, Mayama C, Ishii K, Araie M, 2007. Effects of topical travoprost and unoprostone on optic nerve head circulation in normal rabbits. *Curr Eye Res*; 32(9):743-9.

Ohashi M, Mayama C, Ishi K, Araie M, 2008. Local effect of topical FP-receptor agonists on retinal vessels of the ipsilateral posterior retina in normal rabbit eyes. *Clin Experiment Ophthalmol*; 36(8):767-74.

Okahara A, Tanioka H, Takada K, Kawazu K., 2013. Ocular toxicity of benzalkonium chloride homologs compared with their mixtures. *J Toxicol Pathol*; 26(4):343-9.

Park HY, Kim JH, Lee DE, Lee JH, Park CK, 2011. Changes of the Retina and Intrinsic Survival Signals in a Rat Model of Glaucoma following Brinzolamide and Travoprost Treatments. *Ophthalmic Res*; 46(4):208-217.

Seibold LK, Ammar DA, Kahook MY, 2014. Acute effects of glaucoma medications and benzalkonium chloride on pre-adipocyte proliferation and adipocyte cytotoxicity in vitro. *Curr Eye Res*; 38(1):70-4.

Taketani Y, Yamagishi R, Fujishiro T, Igarashi M, Sakata R, Aihara M, 2014. Activation of the prostanoid FP receptor inhibits adipogenesis leading to deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy. *Invest Ophthalmol Vis Sci*; 55(3):1269-76.

Travatan®, Prescribing Information, 2011. Alcon Laboratories, Fort Worth, Texas, USA.

Travatan® Scientific Discussion. EMEA, 2004.

Travatan SPC, 2014. Summary of Product Characteristics. Alcon Laboratories Ltd, UK

Uematsu M, Kumagami T, Shimoda K, Kusano M, Teshima M, To H, Kitahara T, Kitaoka T, Sasaki H, 2011. Polyoxyethylene hydrogenated castor oil modulates benzalkonium chloride toxicity: comparison of acute corneal barrier dysfunction induced by travoprost z and travoprost. *J Ocul Pharmacol Ther*; 27(5):437-44.

Whitson JT, Cavanagh HD, Lakshman N, Petroll WM, 2006. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. *Adv Ther*; 23(5):663-71.